多发性硬化症、视神经脊髓炎患者及健康受试者的血清白细胞介素-6和白细胞介素-17水平。
Serum levels of IL-6 and IL-17 in multiple sclerosis, neuromyelitis optica patients and healthy subjects.
作者信息
Ashtari Fereshte, Madanian Reyhanehsadat, Shaygannejad Vahid, Zarkesh Sayyed Hamid, Ghadimi Keyvan
机构信息
Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences Isfahan, Iran.
Department of Neurology, School of Medicine, Isfahan University of Medical Sciences Isfahan, Iran.
出版信息
Int J Physiol Pathophysiol Pharmacol. 2019 Dec 15;11(6):267-273. eCollection 2019.
BACKGROUND
Studies reported that evaluating the interleukin serum level of MS and NMO patients is helpful for differentiating these two diseases from each other. This study aimed to compare the level of IL-6 and IL-17 in MS and NMO patients and healthy subjects.
METHODS
This study is a case control study that evaluated the serum level of IL-6 and IL-17 in MS and NMO patients in comparison to controls in patients who referred to Kashani hospital clinics. The level of serum IL-6 and IL-17 were measured by ELISA test in all patients. Participants were divided in to three groups include MS patients, NMO patients and controls and the level of IL-6 and IL-17 were compared in this three groups.
RESULTS
Mean of serum level of IL-6 in the NMO group was significantly lower than MS and healthy subject (P=0.02 for NMO and MS, P=0.001 for NMO and healthy subjects) but there was no significant difference between MS and healthy subjects (P=0.09). The mean of serum level of IL-17 in the MS and NMO were significantly higher than healthy subjects (P<0.001 for both). Also the mean of serum level of IL-17 in the MS was significantly higher than NMO (P=0.01). A positive significant correlation between age and serum level of IL-6 in all subjects (r=0.23, P=0.01). There was a positive significant correlation between age and serum level of IL-17 in MS and NMO patients (r=0.28, P=0.012).
CONCLUSION
Using IL-17 and IL-6 were inflammatory markers to diagnosis of NMO, MS and healthy subjects.
背景
研究报道，评估多发性硬化症（MS）和视神经脊髓炎谱系障碍（NMO）患者的白细胞介素血清水平有助于区分这两种疾病。本研究旨在比较MS和NMO患者以及健康受试者中白细胞介素-6（IL-6）和白细胞介素-17（IL-17）的水平。
方法
本研究为病例对照研究，评估了转诊至卡沙尼医院诊所的患者中，MS和NMO患者与对照组相比的血清IL-6和IL-17水平。所有患者均通过酶联免疫吸附测定（ELISA）检测血清IL-6和IL-17水平。参与者分为三组，包括MS患者、NMO患者和对照组，并比较了这三组中IL-6和IL-17的水平。
结果
NMO组血清IL-6水平均值显著低于MS组和健康受试者（NMO组与MS组比较，P = 0.02；NMO组与健康受试者比较，P = 0.001），但MS组与健康受试者之间无显著差异（P = 0.09）。MS组和NMO组血清IL-17水平均值显著高于健康受试者（两组比较，P均<0.001）。此外，MS组血清IL-17水平均值显著高于NMO组（P = 0.01）。所有受试者中，年龄与血清IL-6水平呈显著正相关（r = 0.23，P = 0.01）。MS和NMO患者中，年龄与血清IL-17水平呈显著正相关（r = 0.28，P = 0.012）。
结论
IL-17和IL-6可作为诊断NMO、MS和健康受试者的炎症标志物。
Zotero 插件